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Summary: Most enzyme deficiencies in humans are inherited as autosomal
recessive traits. The term dominant negative is applied to mutant alleles in which
a mutant protein interferes in one way or another with the function of the normal
protein being produced from the wild-type allele in a heterozygote. Such a domi-
nant negative effect usually involves homomeric or heteromeric proteins.
3-Methylcrotonyl-CoA carboxylase (MCC) is a heteromeric mitochondrial
enzyme comprised of biotin containing MCCa subunits and smaller MCCb sub-
units, encoded by the genesMCCA andMCCB, respectively. Mutations in these
genes cause isolatedMCC deficiency, an autosomal recessive disorder with a vari-
able phenotype ranging from severe neonatal to asymptomatic adult forms.
Patients with MCC deficiency have a characteristic organic aciduria with greatly
increased excretion of 3-hydroxyisovaleric acid (3-HIVA) and 3-methylcrotonyl-
glycine (3-MCG). Here, two patients with elevated excretion of 3-MCG and
3-HIVA and partial deficiency of MCC are discussed, one of them with severe
neurological symptoms. Both showed evidence of biotin responsiveness and were
heterozygous for themissensemutationMCCA-R385S.Evidence is presented that
MCCA-R385S is a dominant negative allele leading to biochemical abnormalities
and clinical symptoms in heterozygous individuals and that it is responsive to phar-
macological doses of biotin in vivo.
SIGNIFICANCE OF DOMINANT AND RECESSIVE MUTANT ALLELES
By definition, a phenotype expressed in the same way in both homozgotes and
heterozygotes is dominant, whereas a phenotype expressed only in homozygotes
or compound heterozygotes (or, for X-linked traits, hemizygotes) is recessive. In
practice, this definition is too rigid to be useful. The distinction between dominant
and recessive inheritance is not absolute and usually refers to the clinical phenotype
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associated with a particular allele. Accordingly, mutant alleles are classified as domi-
nant or recessive on the basis of whether they can cause a change in phenotype when
in the heterozygous or homozygous/compound heterozygous state, respectively.
The majority of enzyme de¢ciencies in humans are inherited as autosomal recessive
traits. Although a recessive phenotype is de¢ned as being clinically undetectable in
heterozygotes, heterozygotes for many of these conditions exhibit subtle di¡erences
in phenotype when examined at the cellular or biochemical level, and these di¡erences
may be enhanced by environmental factors. Even when clinically ‘normal’, individuals
who are heterozygous for recessive loss of function alleles often have demonstrable
metabolic di¡erences and always have demonstrable di¡erences at the protein level.
Such subtle phenotypic e¡ects may be more common than is generally recognized
and may contribute to phenotypes usually considered to be complex traits. For
example, heterozygosity for cystathionine b-synthase-de¢cient homocystinuria is
probably a risk factor for vascular disease (Clarke 2002), dementia and Alzheimer
disease (Loscalzo 2002), and osteoporotic fractures in the elderly (Raisz 2004).
Whether a mutant allele generates a dominant or a recessive disorder is determined
by two factors: (1) the e¡ect of the mutant allele on the function of the gene product,
and (2) the tolerance of the biological system (e.g. the blood glucose homeostatic
system) to perturbation of that particular gene product (Kacser and Burns 1981).
Tolerant systems tend to result in recessive phenotypes, less-tolerant systems tend
to result in dominant phenotypes. Examples where a heterozygous loss-of-function
allele, i.e. haploinsu⁄ciency, causes a disease phenotype include several forms of
porphyria (Anderson et al 2001), familial hypercholesterolaemia (Goldstein et al
2001), and type I osteogenesis imperfecta (Byers and Cole 2002). However, for most
metabolic pathways, quantitative analysis demonstrates that a large change in enzyme
activity results in a negligible change in £ux, which explains why most enzyme
de¢ciencies are recessive (Kacser and Burns 1981).
DOMINANT NEGATIVE EFFECT
Instead of simple deficiency or dysfunction of the protein product of a mutant allele,
an abnormal protein may be synthesized that causes an abnormal phenotype by inter-
fering with the protein product of the normal allele in heterozygous individuals. Such
an effect of the protein product of a mutant allele on the function of the protein
product of the wild-type allele is termed dominant negative. A dominant negative
effect of the protein product of a mutant allele usually involves homomeric or
heteromeric proteins. Typically, the protein product of a dominant negative allele
is functionally inactive and in addition has the property of inhibiting the activity
of the protein product of the normal allele, thus causing the cell to be deficient in
the function of the normal protein product (Herskowitz 1987). To achieve this,
the dominant negative mutant protein product must be stable and able to assemble
into the normal multimeric protein complex. This will lead to the formation of
nonfunctional multimers. Such a mutant allele has a dominant effect because its
phenotype is manifested despite the presence of the wild-type allele.
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SUBUNIT STRUCTURE AND GENE DOSAGE EFFECTS
Evidence for a deviant gene dosage effect at the polypeptide level in cystathionine
b-synthase deficiency (classical homocystinuria) was first reported by Uhlendorf
and colleagues (Uhlendorf et al 1973), reviewed by Mudd and Levy (1978) and later
by McGill and colleagues (McGill et al 1990). They pointed out that the enzymatic
activity in heterozygotes is almost invariably is less than 50% of the mean normal
activity, or on average one-third normal, instead of half-normal (McGill et al 1990).
If a human enzyme possesses at least two copies of any subunit (i.e. if it contains a2),
a tentative explanation for a deviant gene dosage e¡ect, such as the one in classical
homocystinuria, is provided in Figure 1. Let us suppose that there are two copies
of the same subunit, an active, wild-type subunit, a and a mutant inactive subunit,
a0. Heterozygous individuals who synthesize normal and mutant polypeptide chains,
when the mutant allele is stable, are likely to assemble three types of enzyme mole-
cules: aa (wild-type homomeric), a0a0 (mutant homomeric) and aa0/a0a(heterodimeric
hybrid-molecule form) (Figure 1). If it is assumed that a and a0 are present in equal
numbers and that assembly is random, molecules containing aa, aa0/a0a and a0a0 will
represent 25%, 50% and 25% of the total enzyme molecules, respectively. The speci¢c
activity of the native enzyme containing two wild-type alleles may be taken as 100%;
likely the activity of the mutant enzyme containing 2 mutant alleles will be 0%. Thus,
the total activity in the heterozygote will depend upon the activity of the hybrid mol-
ecule. If there is no interaction between the associated normal and mutant polypeptide
chains, the heterozygote will have a total activity of 50% of normal. However, if there
is a (dominant) negative interaction, so that the hybrid molecule form contributes only
a diminished catalytic activity, the heterozygote will have less than 50% of the normal
total activity. In the extreme, the hybrid molecule will have no activity and thus the
Figure 1 Subunit structure and gene dosage e¡ects in a heterozygous individual
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heterozygote total activity would be only 25% (Figure 1). Such an exaggerated gene
dosage e¡ect (negative allelic complementation) is assumed to be the cause of less
than half-normal enzymatic activity in heterozygotes for cystathionine b-synthase-
de¢cient homocystinuria (McGill et al 1990).
3-METHYLCROTONYL-CoA CARBOXYLASE (MCC) DEFICIENCY
3-Methylcrotonyl-CoA carboxylase (MCC, EC 6.4.1.4) is a biotin-dependent enzyme
that catalyses the fourth step in the catabolism of leucine. It carboxylates 3-methyl-
crotonyl-CoA to 3-methylglutaconyl-CoA in an ATP-requiring reaction using bicar-
bonate as the source of the carboxyl group (Sweetman and Williams 2001). MCC is
a heteromeric mitochondrial enzyme comprised of biotin-containing MCCa subunits
and smaller MCCb subunits, encoded byMCCA andMCCB, respectively. Mutations
in these genes cause MCC deficiency (also known as methylcrotonylglycinuria
(Mckusick 210200/210210)), an autosomal recessive disorder with a variable pheno-
type ranging from severe neonatal onset to asymptomatic forms in adults (Baumgart-
ner et al 2001; Gallardo et al 2001). Some patients present in the neonatal period with
seizures and hypotonia (Bannwart et al 1992; Lehnert et al 1996); others are asymp-
tomatic women discovered only by detection of abnormal metabolites in the neonatal
screening samples of their healthy babies (Gibson et al 1998). Most patients, however,
are asymptomatic until an episode of acute metabolic decompensation following
intercurrent illness in early childhood leads to their diagnosis. Patients with MCC
deficiency have a characteristic organic aciduria with greatly increased excretion of
3-hydroxyisovaleric acid (3-HIVA) and 3-methylcrotonylglycine (3-MCG), usually
in combination with a severe secondary carnitine deficiency. In addition, 3-hydroxy-
isovalerylcarnitine is found in blood and urine (Sweetman and Williams 2001).
MCC de¢ciency can be con¢rmed by demonstrating de¢cient MCC activity in the
presence of normal activity of another biotin-dependent carboxylase in cultured skin
¢broblasts or isolated lymphocytes. MCC activity in cultured ¢broblasts of patients
is usually less than 2% of the mean control value. Two patients with higher residual
activity in cultured ¢broblasts varying from 4% to 12% have been reported (Tuchman
et al 1993; Wiesmann et al 1998). No correlation between the level of residual enzyme
activity measured in vitro and clinical presentation has been observed. Here, two
patients with a biochemical and, in one case, a clinical phenotype of MCC de¢ciency,
both responsive to biotin, are discussed (Baumgartner et al 2004).
BIOTIN-RESPONSIVE MCC DEFICIENCY IN TWO HETEROZYGOTES
FOR MCCA-R385S
The first patient presented at 3 months with seizures and progressive psychomotor
retardation. Metabolic investigation at 2 years revealed elevated excretion of 3-MCG
and 3-HIVA, suggesting MCC deficiency. High-dose biotin therapy was associated
with correction of the organic aciduria within 4 weeks, a dramatic reduction in
seizures and normalization of the EEG. The second patient, a newborn detected
by tandem mass spectrometry newborn screening, displayed the same biochemical
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phenotype and remained asymptomatic with biotin up to the present age of 18 months
(Baumgartner et al 2004).
Enzymatic determination of MCC activity in cultured ¢broblasts revealed a partial,
but speci¢c, MCC de¢ciency (Baumgartner et al 2004). In both, residual ¢broblast
MCC activity was not abnormally sensitive to biotin depletion nor was it enhanced
by addition of high concentrations of biotin to the medium. These results rule out
holocarboxylase synthase (HCS) de¢ciency as the cause of reduced MCC activity but
do not explain the clinical features or the persistent organic aciduria in our patients.
Mutation analysis of the MCCA and MCCB genes revealed that both patients
are heterozygous for a previously described missense mutation, MCCA-R385S,
and a known polymorphism,MCCA-P464H (Obata et al 2001). Despite an extensive
search for a functional mutation on the second allele by RT-PCR of mRNA of the
entire MCCA and MCCB ORF as well as by ampli¢cation and sequencing of all
MCCA exons and £anking intronic splice sites from genomic DNA, no other coding
alterations were identi¢ed (Baumgartner et al 2004). In earlier studies,MCCA-R385S
conferred no MCC activity when transfected into reference MCCa-de¢cient cells
(Baumgartner et al 2001). The MCCA-R385S allele was identi¢ed in one of 132
caucasian control chromosomes (Baumgartner et al 2001). Interestingly,
MCCA-R385S appears to be the most frequent allele found inMCC-de¢cient patients
of German origin. Among seven such patients, one is homozygous and six are com-
pound heterozygous for MCCA-R385S (M.R. Baumgartner and M.F. Dantas
unpublished results).
MCCA-R385S EXHIBITS AN ALLELE-SPECIFIC DOMINANT
NEGATIVE EFFECT
The missense allele MCCA-R385S is unusual in that it is the only one of seven
detected in six MCCa-deficient patients for which protein blot analysis of fibroblast
homogenates shows the presence of MCCa protein (CRMþ) (Baumgartner et al 2001;
Gallardo et al 2001).
An arginine at position 385 (or the corresponding position) is strictly conserved in
mammalian, plant, fungal and bacterial carboxylases (Jitrapakdee and Wallace 1999;
Samols et al 1988), and the corresponding residue in the biotin carboxylase domain of
E. coli acetyl-CoA carboxylase (R338) has been shown to be part of a positively
charged pocket for bicarbonate binding (Thoden et al 2000).
To explain the biochemical abnormalities (and clinical phenotype in patient 1) seen
in vivo in these patients, a dominant negative in£uence of the mutant R385S MCCa
subunit on the activity ofMCCA-wild type was hypothesized. To test this, both alleles
were cotransfected into an SV40T-transformedMCCa-de¢cient reference cell line and
MCC activity was measured 72 h later. In two separate experiments, cotransfection of
MCCA-wild type allele with vector without insert restored MCC activity to 55% of
untransfected control ¢broblasts while cotransfection of MCCA-wild type with
MCCA-R385S restored MCC activity only to 25%, i.e. to about 50% of that obtained
with wild type coexpressed with vector without insert (Figure 2) (Baumgartner et al
2004). In contrast, co-transfection of MCCA-wild type with either MCCA-A289V
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or MCCA-L437P restored MCC activity to the same level as that obtained with wild
type coexpressed with vector without insert (Figure 2). Thus, the reduction of
MCC activity is speci¢c for MCCA-R385S. The same experiment using the
MCCA-wild type construct with histidine instead of a proline at codon 464
(MCCA-P464H) gave similar results (Baumgartner et al 2004). Thus, the dominant
negative e¡ect of MCCA-R385S when coexpressed with the wild-type allele is inde-
pendent of the P464H polymorphism.
MCCa R385S ful¢lls all of the above-mentioned criteria of a dominant negative
allele: in contrast to the protein products of otherMCCA missense alleles, the MCCa
R385S protein is stable (Baumgartner et al 2001; Gallardo et al 2001). On protein blot
analysis using avidin alkaline phosphatase as a probe, MCCa R385S accumulates to
levels equal to or even greater than normal (Baumgartner et al 2001). Despite this,
expression studies clearly show that the MCCa R385S is catalytically inactive (Baum-
gartner et al 2001; Desviat et al 2003). Moreover, the results of cotransfection experi-
ments show that expression of MCCa R385S but not two other MCCA missense
alleles inhibits the function of coexpressed wild-type MCCa protein (Baumgartner
et al 2004). Taken together, these data strongly support the hypothesis of a dominant
negative e¡ect of MCCa R385S on the wild-type protein and thus on MCC activity.
Additional evidence comes from the recent studies of Sloane and Waldrop, who
used the puri¢ed homodimer of the biotin carboxylation subunit of E. coli acetyl-CoA
carboxylase to study the kinetic properties of mutant proteins (Sloane and Waldrop
2004). They showed that E. coli biotin carboxylase-R338S, the missense mutant cor-
responding to MCCA-R385S, exhibited a dominant negative e¡ect on the function
Figure 2 The e¡ect of coexpression of MCCA missense alleles and wild-type MCCA.
MCC-de¢cient cells were cotransfected with wild-type MCCA plus MCCA alleles with the
indicated missense mutation. Activities represent mean and range of duplicates. MCC activity
of cells cotransfected with wild-type MCCA and vector without insert was set at 100%. Modi-
¢ed from Baumgartner et al (2004)
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of the wild-type active site by negative cooperativity with respect to bicarbonate con-
centration (Sloane and Waldrop 2004). Furthermore, they presented evidence that the
degree of negative cooperativity is decreased upon increasing concentrations of biotin.
These data support the hypothesis of a dominant negative e¡ect of MCCa R385S on
the wild-type protein and thus on MCC activity.
WHY ARE OTHER MCCA-R385S HETEROZYGOTES ASYMPTOMATIC?
The MCCA-R385S heterozygotes with normal urinary organic acids studied in our
laboratory were all adults. Thus, one possible explanation is that the metabolic flux
through the pathway is less in adults than in infants and children. This would be
consistent with the identification of asymptomatic adults with severe MCC deficiency
(Baumgartner et al 2001; Gibson et al 1998). Additional factors that could influence
the phenotypic consequences of MCC deficiency include the extent to which the
pathway is stressed by dietary or other factors (e.g. excessive protein breakdown
associated with an intercurrent infection).
Alternatively, the amount of functional MCCa produced from the wild-type allele
may vary. Recent studies have suggested that alleles of as many as half of all genes
examined exhibit a 2^4-fold or more allelic variation in expression and that this
characteristic segregates with the alleles from one generation to the next (Lo et al
2003; Yan et al 2002). If this is the case for MCCA, then the expression level of
the wild-type allele would be an additional variable a¡ecting the consequences of
heterozygosity for a nonfunctional allele. A heterozygote with a low-expressing
wild-type allele might be clinically and/or biochemically symptomatic. Conversely,
a heterozygote with a high-expressing wild-type allele would be normal. However,
allelic expression studies showed about equal expression of both alleles in the two
patients (Baumgartner et al 2004).
Finally, normal variation in genes whose protein products have the potential to
modify the function of MCC or the £ux through the pathway could also in£uence
the phenotype of MCC de¢ciency. MCCB and HCS are obvious candidate modi¢er
genes for MCCA, but no sequence variation in either of these was found in our
patients (Baumgartner et al 2004).
Surprisingly, the clinical symptoms in patient 1 and the biochemical phenotype in
both patients appeared to respond to high doses of biotin. A biotin-responsive form
of MCC de¢ciency has not previously been reported (Sweetman and Williams 2001).
Biotin responsiveness, however, is consistent with the observation thatMCCA-R385S
produces a stable protein and that other cofactor-responsive disorders are allele
speci¢c (e.g. holocarboxylase synthetase de¢ciency) (Dupuis et al 1999). It also is
in accordance with the ¢ndings of Sloane and Waldrop, who showed that biotin
decreases the negative cooperativity of E. coli biotin carboxylase with a missense
mutation in the residue corresponding toMCCA-R385S (Sloane and Waldrop 2004).
To provide further evidence for biotin responsiveness, additional clinical, biochemical
and molecular studies on and o¡ biotin are needed.Therefore, careful documentation
of the consequences of biotin administration in newly diagnosed patients is
recommended.
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